Adams C, Mahler S B C, Daas L, Langenbucher A, Seitz B
Klinik für Augenheilkunde, Universitätsklinikum des Saarlandes UKS, Kirrberger Str. 100, 66424, Homburg/Saar, Deutschland.
Experimentelle Ophthalmologie, Universitätsklinikum des Saarlandes UKS, Homburg/Saar, Deutschland.
Ophthalmologie. 2022 Sep;119(9):945-951. doi: 10.1007/s00347-022-01610-w. Epub 2022 Mar 23.
Excimer laser-assisted phototherapeutic keratectomy (PTK) has become established as the gold standard in treatment of epithelial basement membrane dystrophy (EBMD), commonly also known as map-dot-fingerprint dystrophy (MDF). At the Department of Ophthalmology, Saarland University Medical Center in Homburg/Saar, systems from Zeiss Meditec and Schwind have been used. The outcomes of both were compared in this study.
The retrospective study included patients who underwent PTK with a diagnosis of MDF between 2007 and 2017. A total of 170 operations were performed using Zeiss Meditec MEL-70 (Carl Zeiss Meditec AG, Jena, Germany) and 98 using a Schwind eye-tech-solutions Amaris 750S laser (Schwind eye-tech-solutions GmbH, Kleinostheim, Germany). Preoperative and postoperative data for visual acuity, refraction and astigmatism as well as curvature data from the Pentacam and endothelial cell count were collected. The follow-up period averaged 8 months.
In both groups visual acuity postoperatively was significantly better (Zeiss: p < 0.001, Schwind p < 0.004). The improvement in the Schwind group was less than in the Zeiss group, which is the reason why there was a significant difference between the laser systems postoperatively (p < 0.017). There were no significant changes regarding the spherical equivalent after PTK. Regarding astigmatism, there was a significant decrease in the Zeiss group (p < 0.042), while it did not change significantly in patients treated with Schwind laser (p < 0.217). Overall, this led to a significant postoperative difference between both laser systems (p < 0.014).
The PTK can be recommended as an effective treatment method for patients with EBMD, regardless of the laser systems used. Patients benefit from long relief from recurrences with improved or constant visual acuity and stable refraction.
准分子激光辅助光治疗性角膜切削术(PTK)已成为治疗上皮基底膜营养不良(EBMD)的金标准,EBMD通常也被称为地图-点状-指纹状营养不良(MDF)。在萨尔州洪堡大学医学中心眼科,使用了蔡司医疗技术公司和施温德公司的设备。本研究对两者的治疗效果进行了比较。
这项回顾性研究纳入了2007年至2017年间诊断为MDF并接受PTK治疗的患者。使用蔡司医疗技术公司的MEL-70(德国耶拿卡尔蔡司医疗技术股份公司)共进行了170例手术,使用施温德眼科技解决方案公司的阿玛里斯750S激光(德国克莱诺施泰姆施温德眼科技解决方案有限公司)进行了98例手术。收集了术前和术后的视力、屈光和散光数据,以及Pentacam的曲率数据和内皮细胞计数。随访期平均为8个月。
两组术后视力均显著提高(蔡司组:p<0.001,施温德组:p<0.004)。施温德组的改善程度低于蔡司组,这就是术后激光系统之间存在显著差异的原因(p<0.017)。PTK术后等效球镜度无显著变化。关于散光,蔡司组有显著降低(p<0.042),而使用施温德激光治疗的患者散光无显著变化(p<0.217)。总体而言,这导致了两种激光系统术后存在显著差异(p<0.014)。
无论使用何种激光系统,PTK均可作为EBMD患者的有效治疗方法推荐。患者可长期受益于复发缓解,视力改善或稳定,屈光稳定。